Esbriet

Treatment with Esbriet (pirfenidone, Genentech) or Ofev (nintedanib, Boehringer Ingelheim), or with steroids was found to be safe for idiopathic pulmonary fibrosis (IPF) patients needing a bilateral lung transplant (BLTx), a study reports. ... Read more

May 4, 2018May 4, 2018

Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study

Esbriet, News

A combined treatment, pirfenidone and rapamycin, worked to prevent fibrosis in lung fibroblasts from patients with idiopathic pulmonary fibrosis, new research showed, suggesting a possibly more effective way of treating IPF. ... Read more

March 5, 2018March 5, 2018

Boehringer Ingelheim Launches ‘Why Wait in IPF?’ Campaign, Raising Awareness of Early Diagnosis

Esbriet, News

On last week’s Rare Disease Day, held Feb. 28, Boehringer Ingelheim launched a new campaign titled “Why Wait in IPF?” to raise awareness about the importance of early diagnosis of ... Read more

February 14, 2018February 14, 2018

Advocacy Groups Oppose NICE Opinion Limiting Esbriet to Select IPF Patients in UK

Esbriet, News

patientMpower, a U.K. digitial healthcare and advocacy company, joined others in voicing disappointment with the recent decision of a British advisory board to restrict the use of Esbriet (pirfenidone) to ... Read more

December 20, 2017December 20, 2017

Lung Cancer in IPF Patients Best Treated on ‘Do No Harm’ Basis, Commentary Argues

Esbriet, News

The management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer should follow the premise “first, do no harm,” researchers argue in the journal The Lancet Respiratory Medicine. ... Read more

November 20, 2017November 20, 2017

Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds

Esbriet, News

Despite the availability of approved antifibrotic treatments for idiopathic pulmonary fibrosis (IPF), many patients in Europe do not receive them, partly due to a lack of awareness by physicians ... Read more

November 7, 2017November 7, 2017

Esbriet Reduces Cough in Patients with Idiopathic Pulmonary Fibrosis, Dutch Study Shows

Esbriet, News

Treatment with Esbriet (pirfenidone) reduces cough in patients with idiopathic pulmonary fibrosis (IPF), a new European study finds. The study, “Effect of pirfenidone on cough in patients with idiopathic pulmonary ... Read more

October 20, 2017October 20, 2017

Interview: RECAP Trial Confirms Esbriet’s Long-Term Safety Profile

Esbriet, News

Results from the RECAP clinical trial, which was conducted over five years, support the long-term safety of Esbriet (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF). The study, “An Open-Label ... Read more

September 22, 2017September 22, 2017

Esbriet Seen to Offer Significant Benefits to IPF Patients in Pooled Analysis of Phase 3 Trials

Esbriet, News

A post-hoc analysis of data from Phase 3 studies shows that Esbriet (pirfenidone) can significantly reduce the incidence of disease progression events in people with idiopathic pulmonary fibrosis (IPF) — including ... Read more

September 12, 2017September 12, 2017

Ofev-Esbriet Combo Is as Safe as Individual Components as a Pulmonary Fibrosis Therapy, Trial Indicates

Esbriet, News

A combination of Ofev (nintedanib) and Esbriet (pirfenidone) is as safe a therapy for idiopathic pulmonary fibrosis as the individual components alone, a Phase 4 clinical trial indicates. Preliminary trial findings ... Read more

Esbriet

Esbriet and Ofev Use Prior to Lung Transplant Seen as Safe for IPF Patients in Study

Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study

Boehringer Ingelheim Launches ‘Why Wait in IPF?’ Campaign, Raising Awareness of Early Diagnosis

Advocacy Groups Oppose NICE Opinion Limiting Esbriet to Select IPF Patients in UK

Lung Cancer in IPF Patients Best Treated on ‘Do No Harm’ Basis, Commentary Argues

Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds

Esbriet Reduces Cough in Patients with Idiopathic Pulmonary Fibrosis, Dutch Study Shows

Interview: RECAP Trial Confirms Esbriet’s Long-Term Safety Profile

Esbriet Seen to Offer Significant Benefits to IPF Patients in Pooled Analysis of Phase 3 Trials

Ofev-Esbriet Combo Is as Safe as Individual Components as a Pulmonary Fibrosis Therapy, Trial Indicates

Pin It on Pinterest